Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis

References

• Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287-333
   PubMed Web of Science ®Google Scholar
• British Pain Society. Opioids for persistent pain: good practice. The British Pain Society, 2010;1-36
   Google Scholar
• Belsey J. Primary care workload in the management of chronic pain. A retrospective cohort study using a GP database to identify resource implications for UK primary care. J Med Econ 2002;5:39-50
   Google Scholar
• Wenig CM, Schmidt CO, Kohlmann T, et al. Costs of back pain in Germany. Eur J Pain 2009;13:280-6
   PubMed Web of Science ®Google Scholar
• O'Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 2009;27:95-112
   PubMed Web of Science ®Google Scholar
• Gupta A, Mehdi A, Duwell M, et al. Evidence-based review of the pharmacoeconomics related to the management of chronic nonmalignant pain. J Pain Palliat Care Pharmacother 2010;24:152-6
   PubMedGoogle Scholar
• Kurz A, Sessler DI. Opioid-induced bowel dysfunction. Pathophysiology and potential new therapies. Drugs 2003;63:649-71
   Google Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182:S11-18
   PubMed Web of Science ®Google Scholar
• Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007;61:1181-7
   PubMed Web of Science ®Google Scholar
• Kwong W, Diels J, Kavanagh S. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain. Pain Management 2010;44:630-40
   Google Scholar
• Iyer S, Davis KL, Candrilli S. Opioid use and patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care 2010;19:44-51
   PubMedGoogle Scholar
• Hjalte F, Berggren A-C, Bergendahl H, et al. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manage 2010;40:696-703
   PubMed Web of Science ®Google Scholar
• Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64
   PubMed Web of Science ®Google Scholar
• Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008;24:3503-12
   PubMed Web of Science ®Google Scholar
• Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9:1144-54
   PubMed Web of Science ®Google Scholar
• Löwenstein O, Leyendecker P, Hopp M, et al. Combined prolonged release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009;10:531-43
   PubMed Web of Science ®Google Scholar
• Rentz AM, Yu R, Müller-Lissner S, et al. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009;12:371-83
   PubMedGoogle Scholar
• Ueberall M, Müller-Lissner S, Buschmann-Kramm C, et al. The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res 2011;39:41-50
   PubMed Web of Science ®Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision Making for Health Economic Evaluation. Oxford: Oxford University Press, 2006
   Google Scholar
• Napp Pharmaceuticals Limited. Data on file. Average length of treatment on oxycodone (data obtained from CSD)
   Google Scholar
• Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship?. Health Qual Life Outcomes 2009;7:27-38
   PubMed Web of Science ®Google Scholar
• British National Formulary 60 (September 2010). London: British Medical Association/Royal Pharmaceutical Society, 2010
   Google Scholar
• Curtis L. Unit costs of health and social care 2010. Available at: http://www.pssru.ac.uk/pdf/uc/uc2010/uc2010.pdf [last accessed June 2011]
   Google Scholar
• Department of Health. National Tariff 2010-2011. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/[last accessed June 2011]
   Google Scholar
• Napp Pharmaceuticals Limited. Data on file. Opioid induced constipation – market research with GPs (n = 100)
   Google Scholar
• Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010;64:763-74
   PubMed Web of Science ®Google Scholar
• Ware Jr JE, Kosinski M, Dewey JE. How to score Version 2 of the SF-36® Health Survey. Lincoln, RI: QualityMetric Incorporated, 2000
   Google Scholar
• Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14: 487-96
   PubMed Web of Science ®Google Scholar
• Willan AR, Briggs AH. Statistical Analysis of Cost Effectiveness Data. Chichester: John Wiley and Sons, 2006
   Google Scholar
• Gaujoux-Viala C, Rat A-E, Guillemin F, et al. Comparison of the EQ-5D and the SF-6D utility measures in 813 patients with early arthritis: results from the ESPOIR cohort. J Rheumatol 2001;38:8;doi:10.3899/jrheum.101006
   Google Scholar
• Marra CA, Woolcott JC, Kopec JA, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571-82
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005;43:736-49
   PubMed Web of Science ®Google Scholar
• Brazier JE, Roberts JR. The estimation of a preference-based index from the SF-12. Med Care 2004;42:851-9
   PubMed Web of Science ®Google Scholar
• Penning-van Beest FJA, van den Hank P, Klok RM, et al. Quality of life in relation to constipation among opioid users. J Med Econ 2010;13:129-35
   PubMedGoogle Scholar
• Guest J, Clegg J, Helter M. Cost-effectiveness of macrogol 4000 compared to lactulose in the treatment of chronic functional constipation in the UK. Curr Med Res Opin 2008;24:1841-52
   PubMed Web of Science ®Google Scholar
• Van der Linden MW, van den Haak P, Penning-van Beest FJA, et al. Patient reported quality of life in cancer patients on opioid therapy is influenced by constipation. Value Health 2008;11:A485
   Google Scholar
• National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008. Available at: http://www.nice.org.uk/aboutnice/howwework/devnicetech/guidetothemethodsoftechnologyappraisal.jsp [last accessed January 2012]
   Google Scholar
• Scottish Medicines Consortium. Advice on oxycodone/naloxone 10 mg/5 mg and 20 mg/10 mg prolonged release tablets (Targinact®). February 2009. Available at: http://www.scottishmedicines.org.uk/files/oxycodonenaloxone_Targinact_.pdf [last accessed January 2012]
   Google Scholar
• Schutter U, Grunert S, Meyer C, et al. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin 2010;26:1377-87
   PubMed Web of Science ®Google Scholar
• Rychlik R, Kiencke P, Kresimon J. [Healthcare research study into quality of life and pharmacoeconomic aspects of patients with chronic back pain being treated with oxycodone/naloxone or other WHO step III opioids. Interim analysis]. Gesundh Ökon Qual Manag 2011;16:10-9. German
   Google Scholar
• Candy B, Jones L, Drake R, et al. Laxatives or methylnaltrexone for the management of constipation in palliative care (review). The Cochrane Library 2011, Issue 1. Available at: http://www.thecochranelibrary.com [last accessed January 2012]
   Google Scholar
• NHS Clinical Knowledge Summaries. Palliative care - pain - management. Available at: http://www.cks.nhs.uk/palliative_cancer_care_constipation [last accessed January 2012]
   Google Scholar
• Scottish Intercollegiate Guidelines Network. Control of pain in adults with cancer. November 2008. Available at http://www.sign.ac.uk/pdf/SIGN106.pdf [last accessed January 2012]
   Google Scholar
• Napp Pharmaceuticals Limited. Data on file. Prescribing of laxatives with opioids – GPRD study
   Google Scholar
• Lanza P, Carey M. The impact of opioid and laxative prescribing habits on constipation in the primary care setting before and after the introduction of SIGN 44: Control of pain in patients with cancer. Primary Health Care Research and Development 2006;7:3-9
   Google Scholar
• Weinberg AD, Minaker KL, AMA Council on Scientific Affairs. Dehydration. evaluation and management in older adults. JAMA 1995;274:1552-6
   Google Scholar